Citations

Clear

6273 citation(s) found for "To, Andrew".

SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome
Gajjar, Aryan , Raju, Arvind Kumar Venkataramana , Gajjar, Amar , Menon, Mythili, Shah, Syed Asfand Yar , Weinberg, Andrew M., Raju, Arvind Kumar , Gajjar, Amani, Dani, Sourbha S.

Mayo Clinic

Biomedicines | August 7, 2025 | Volume: 13 | Issue: 8 | Pages: 1924

10.3390/biomedicines13081924 | PMID 40868177 Get It

Cardiovascular–Kidney–Metabolic (CKM) syndrome symbolizes a single pathophysiologic entity including obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. These conditions altogether accelerate adverse outcomes when they coexist. Recent evidence has shown that the function of glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium–glucose cotransporter-2 inhibitors (SGLT2i) alleviate stress on multiple organs. SGLT2i has been demonstrated to benefit heart failure, hemodynamic regulation, and renal protection while GLP-1RA on the other hand has been shown to demonstrate a strong impact on glycemic management, weight loss, and atherosclerotic cardiovascular disease. This review will aim to understand and evaluate the mechanistic rationalization, clinical evidence, and the potential therapeutic treatment of SGLT2 inhibitors and GLP-1 receptor agonists to treat individuals who have CKM syndrome. This analysis also assesses whether combination therapy can be a synergistic approach that may benefit patients but is still underutilized because of the lack of clear guidelines, the associated costs, and disparities in accessibility. Therefore, in this review, we will be discussing the combination therapy’s additive and synergistic effects, current recommendations and clinical evidence, and mechanistic insights of these GLT2 inhibitors and GLP-1 receptor agonists in CKM syndrome patients. Overall, early and combination usage of GLP-1RA and SGLT2i may be essential to demonstrating a significant shift in modern cardiometabolic therapy toward patient-centered care.
Four-Dimensional Computed Tomography-Derived Radiolunate Arthrokinematics With a Case Study in Four-Corner Arthrodesis
Trentadue, Taylor P. , Thoreson, Andrew R. , Lopez, Cesar , Leng, Shuai, Amadio, Peter C. , Kakar, Sanjeev , Zhao, Kristin D. , Amadio, Peter, Kakar, Sanjeev , Trentadue, Taylor P , Trentadue, Taylor P , Leng, Shuai

Mayo Clinic

HAND | August 7, 2025 | Volume: 21 | Issue: 8 | Pages: 1286-1296

10.1177/15589447251352124 | PMID 40770847 Get It

Background: The radiolunate joint is conventionally thought to be spared from radiocarpal osteoarthritis, but proximal lunate degenerative changes have been noted. An investigation of radiolunate arthrokinematics in ostensibly healthy wrists may improve understanding of posttraumatic and postoperative outcomes. We hypothesize that four-dimensional computed tomography (4DCT)-derived radiolunate arthrokinematics during motion will differ between wrists with type 1 and type 2 lunates. The clinical-translational relevance of this analysis is highlighted using a 4DCT case study of scaphoid excision with 4-corner arthrodesis (SEFCA). Methods: Four-dimensional computed tomography data were collected during flexion-extension and radioulnar deviation in 19 healthy wrists (mean [SD] age: 43.6 [11.7] years, 21.1% female) and 1 wrist 3 years after SEFCA (male, 52 years). Carpal osteokinematics and joint arthrokinematics were calculated to derive median radiolunate interosseous proximities at each 4DCT-captured timepoint. Results: Median radiolunate interosseous proximities during motion are well approximated by second-order regressions in uninjured wrists. In the arthrodesed wrist, closest proximities occurred at the extremes of motion except maximum radial deviation. Conclusions: This study quantifies a normative range of median radiolunate interosseous proximities during wrist motion. The normative 4DCT datasets provide a reference range for evaluating postoperative arthrokinematics, suggesting the clinical-translational potential of dynamic imaging. The case study highlights applications for patient-level postoperative evaluation, which can be expanded to other pathologies, surgeries, or conditions in the future.
Characterizing primary mediastinal large B-cell lymphoma based on molecular classification: a multi-center retrospective pilot study
Superdock, Michael , Rimsza, Lisa M. , Strawderman, Myla , Ramsower, Colleen , Steiner, Raphaël , Faugh, Tina, Maurer, Matthew J. , Feldman, Andrew L., Rock, Philip , Robetorye, Ryan S. , Flowers, Christopher R. , Friedberg, Jonathan W. , Maurer, Matthew , Rosenthal, Allison C, Wallace, Danielle , Link, Brian K. , Rosenthal, Allison , Burack, Richard , Syrbu, Sergei , Feldman, Andrew L. , Cerhan, James R. , Casulo, Carla

Mayo Clinic

Leukemia & Lymphoma | August 6, 2025 | Volume: 66 | Issue: 12 | Pages: 2324-2327

10.1080/10428194.2025.2539231 | PMID 40768371 Get It

Global Variations in Practices After Bariatric and Metabolic Surgery; the PARTNER study
Clyde, Danielle , Grant, Callum, Canales, Juan Andres Aguiar, Adib, Reza, Baig, Sarfaraz Jalil , Bhasker, Aparna Govil , Beaux, Andrew de, Drummond, Gillian, Fawal, Hayssam, Goodpaster, Kasey , Hopkins, George, Jatana, Anita , Kothari, Shanu N. , Kow, Lillian, Faria, Sílvia Leite , Madhok, Brij, Mahon, David, Miller, Karl , Nimeri, Abdelrahman , O’Kane, Mary , Poggi, Luis , Ratcliffe, Denise , Sarkar, Rupa , Shenfine, Jon, Sogg, Stephanie , Suter, Michel , Taha, Safwan , Voon, Kelvin , Lamb, Peter , Mahawar, Kamal , Grant, Callum, Canales, Juan Andres Aguiar, Cameron, David, Copăescu, Cătălin , Clare, Ken , Fried, Martin , Graham, Yitka N. H. , Goel, Ramen , Hazebroek, Eric J. , Husain, Farah Anwari , Joyce, Brian, Kermansaravi, Mohammad , Miras, Alexander Dimitri , Moizé, Violeta , Neto, Manoel Galvão , Peterli, Ralph , Sakran, Nasser , Salminen, Paulina , Singhal, Rishi , Stenberg, Erik , Tahrani, Abd A. , Vilallonga, Ramón , Welbourn, Richard , Zerrweck, Carlos , Moussa, Osama , Byrne, James Patrick , Parmar, Chetan D. , Ghanem, Omar M. , Robertson, Andrew G. , Yang, Wah

Mayo Clinic

No container title available | August 6, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6779565/v1 Get It

Abstract Background: With over 1 billion individuals affected globally, obesity and obesity related diseases is now a leading cause of death. Metabolic and bariatric surgery (MBS) has emerged as a cornerstone intervention for severe obesity and its associated comorbidities. Despite its efficacy, postoperative care and follow-up after MBS remains highly variable worldwide. Objective: The PARTNER study aimed to evaluate global clinical practices in the postoperative management following MBS by surveying multidisciplinary healthcare professionals . Methods: This study was an international online survey conducted between October 2024 and January 2025. A multidisciplinary team developed the questionnaire based on existing literature and international guidelines. The survey assessed five domains: follow-up care, postoperative treatment, dietary management, patient support, and measurement of surgical outcomes. Responses were analysed descriptively. Results: A total of 262 responses were received from 62 countries. Most respondents were bariatric surgeons (72.1%) working in public healthcare systems (73.3%). While 78.7% reported conducting three-month postoperative reviews, only 23.7% offered indefinite follow-up. Hybrid models of care (virtual and in-person) were common (56.9%). VTE prophylaxis and postoperative PPI use were recommended by 64.1% and 84.3% respectively. Nearly all respondents (98.1%) provided dietary advice, with protein and micronutrient supplementation widely endorsed. Only 56.1% routinely referred patients for psychological follow-up. Definitions of surgical success and failure varied widely, with inconsistent objective outcome measures. Conclusion: The PARTNER study reveals significant international variation in postoperative management practices following MBS. These findings underscore the need for more standardized, evidence-based guidelines to improve long-term outcomes and equity of care worldwide.
Treatment and outcomes of progression of disease post–CAR T-cell therapy in mantle cell lymphoma: a multicenter analysis
Epstein‐Peterson, Zachary D. , Lionel, Anath C. , Joseph, Ashlee , Drill, Esther , Atallah‐Yunes, Suheil Albert , Brooks, Taylor , Chong, Elise A. , Chong, Emeline R. , Cruz, Jamie Dela , Frank, Matthew J. , Jacobson, Caron A. , Beyar‐Katz, Ofrat , Maddocks, Kami J. , McLoughlin, Daniel E. , Navalekar, Rohin, Ryan, Christine E. , Sauter, Craig S. , Sharma, Samanvaya , Shukla, Navika , Therwhanger, Dylan , Besien, Herman J. van, Varon, Ben , Yamshon, Samuel , Palomba, M. Lia , Kumar, Anita , Brooks, Taylor R , Kamdar, Manali , Karmali, Reem , Matasar, Matthew , McLoughlin, Daniel , Rhodes, Joanna , Riedell, Peter A , Ryan, Christine E , Salles, Gilles A , Sawalha, Yazeed , Sharma, Samanvaya , Shouval, Roni , Therwhanger, Dylan , van Besien, Herman , Varon, Ben , Wang, Yucai , Yamshon, Samuel , Zelenetz, Andrew D , Jain, Preetesh , Kumar, Anita , Chong, Elise A , Joseph, Ashlee , Atallah-Yunes, Albert , Ip, Andrew , Iqbal, Madiha , Kamdar, Manali , Karmali, Reem , Matasar, Matthew J. , Merryman, Reid W. , Muñoz, Javier , Navalekar, Rohini, Rhodes, Joanna , Riedell, Peter A. , Salles, Gilles , Sawalha, Yazeed , Wang, Yucai , Zelenetz, Andrew D. , Jain, Preetesh

Mayo Clinic

Blood Advances | August 5, 2025 | Volume: 9 | Issue: 21 | Pages: 5654-5662

10.1182/bloodadvances.2025016315 | PMID 40763269 Get It

Abstract The treatment patterns and clinical outcomes for patients experiencing progression of disease (POD) following CD19-directed chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) mantle cell lymphoma (MCL) are undefined. We identified all patients who received CD19-directed CAR T-cell therapy for R/R MCL therapy across 15 international centers, and studied those experiencing POD post–CAR T-cell therapy in detail. We extracted clinical/treatment/pathologic variables, and associated these features with survival outcomes. In total, 384 patients received CAR T-cell therapy, and 135 (35%) experienced POD. POD occurred at a median of 6 months following CAR T-cell therapy infusion, and most (64%) patients with POD had complete response as best response to CAR T-cell therapy. Tumor features at POD included blastoid/pleomorphic morphology in 29 of 78 (37%) patients, and TP53 mutation in 21 of 41 (51%) patients. Following POD, 17 patients received no further therapy, 13 underwent local therapy, and 105 received systemic therapy. The most common first-line systemic therapies were chemo(immuno)therapy (22 patients; overall response rate [ORR], 40%), pirtobrutinib (17 patients; ORR, 36%), and bispecific antibodies (13 patients; ORR, 67%). Among patients experiencing POD, the median progression-free survival and overall survival (OS) were 2.5 months and 5.4 months, respectively, from POD. Lack of response to CAR T-cell therapy and short time from CAR T-cell therapy infusion to POD (<3 vs 3-6 vs >6 months), among other factors, were associated with inferior OS after POD. In conclusion, we confirm the challenging prognosis for patients experiencing POD following CD19 CAR T-cell therapy for R/R MCL, and establish a benchmark for future investigations in this patient population.
Multimorbidity burden predicts lower likelihood of remission and higher likelihood of disease flare in patients with rheumatoid arthritis
Montes, Daniel , Myasoedova, Elena , Kodishala, Chanakya , George, Roslin Jose , Hanson, Andrew C. , Kronzer, Vanessa L. , Crowson, Cynthia S. , Crowson, CS , Kronzer, Vanessa L , Myasoedova, Elena , Davis, John M.

Mayo Clinic

RMD Open | August 5, 2025 | Volume: 11 | Issue: 3 | Pages: e005577

10.1136/rmdopen-2025-005577 | PMID 40764086 Get It

Objectives To examine associations between multimorbidity, the social determinants of health (SDoHs) and rheumatoid arthritis (RA) flare and remission. Methods All patients aged ≥18 years in Olmsted County, Minnesota, with incident RA in 1999–2014 were identified. Using a list of 55 chronic medical conditions, multimorbidity was defined as the presence of ≥2 conditions and substantial multimorbidity as ≥5 conditions. The Area Deprivation Index and Social Vulnerability Index (SVI) were used as proxies for adverse SDoH burden. Flare and remission were defined using Outcome Measures in Rheumatoid Arthritis Clinical Trials definitions. Mixed effects models were used to assess associations between flare/remission and multimorbidity, adverse SDoH burden and other patient characteristics. Results This study included 659 patients with incident RA. Multimorbidity and substantial multimorbidity predicted 29% (OR:1.29, 95% CI:1.04 to 1.59) and 26% (OR:1.26, 95% CI:1.03 to 1.53) higher odds of flare, respectively. Both were associated with 34% (OR:0.66, 95% CI:0.49 to 0.90) and 33% (OR:0.67, 95% CI:0.51 to 0.90) lower odds of remission, respectively. SVI predicted 8% lower odds of remission for every 0.1 increase above 0.3 (OR:0.92, 95% CI:0.85 to 0.99). Flare was also associated with female sex, smoking, younger age and shorter disease duration, but not seropositivity. Remission was also associated with male sex, never smoking, older age and longer disease duration, but not seropositivity. Conclusions Multimorbidity predicts higher odds of RA flare and lower odds of remission. Adverse SDoH burden predicts lower odds of remission. These findings have the potential to inform disease prognostication and clinician interventions.
Psychomotor Skill Transfer Between Non-Patient and Patient Training: A Point-of-Care Ultrasound Use Case
Breunig, Michael , Hanson, Andrew C. , Kingsley, Ryan , Kashiwagi, Deanne T.

Mayo Clinic

No container title available | August 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7012113/v1 Get It

Abstract Purpose : While it’s commonplace in medical education to train learners using simulated patient encounters, task trainers, or by practicing skills on healthy volunteers, little is known about how well learning and skills transfer to patient care. The purpose of this research is to quantify Point-of-Care Ultrasound (POCUS) skill transfer to patient care through performance assessment. Method : A quantitative analysis of aggregated data consisting of image quality of student-performed POCUS examinations from one midwestern Physician Assistant program was performed. Probabilities for scores of 1-2, 3, 4, and 5 were estimated using a multivariable cumulative logit model. Results : Forty-six PA students were included in the study. A total of 6,218 POCUS examinations were included; 4,506 on non-patients, and 1,712 on patients. When evaluating skill transfer from non-patients to patients, the probability of obtaining a high-quality examination decreases significantly, with a more substantial decrease in performance on more complex skills. The probability of a high-quality examination on the twenty-fifth examination was the highest when learning transfer happened earlier. Conclusion : While training medical providers using non-patient experiences is common, educators must understand the significant loss of quality upon skills transfer to patient care. More complex or higher risk skills likely require close monitoring at the point of skill transfer, to support the learner and ensure patient safety. Based on the findings of this research, earlier skill transfer is associated with worse immediate performance but better long-term re-learning outcomes. Increased deliberate practice prior to skill transfer is associated with better first-time performance on actual patients.
Use of Personalized Body-Worn Alcohol Dispenser, Without Practitioner Feedback, on Bacterial Transmission, Hourly Hand Decontamination Events, and Practitioner Hand Contamination: A Multicenter Randomized Controlled Study
Dexter, Franklin , Togioka, Brandon M. , Simmons, Colby G. , Parra, Michelle C. , Koff, Matthew D. , Wanta, Brendan T., Fernandez, Patrick, Charnin, Jonathan E. , Loftus, Randy W. , Pugely, Andrew J. , Brown, Jeremiah R.

Mayo Clinic

Anesthesia & Analgesia | August 4, 2025 | Volume: 142 | Issue: 1 | Pages: 205-209

10.1213/ane.0000000000007671 | PMID 40758582 Get It

Standardized Clinical Terms and Definitions for Interstitial Lung Disease: A Consensus Statement from the Fleischner Society
Ryerson, Christopher J. , Bankier, Alexander A. , Beasley, Mary Beth , Brown, Kevin M. , Colby, Thomas V. , Cottin, Vincent , Galvin, Jeffrey R. , Hariri, Lida P. , Johkoh, Takeshi , Lee, Ho Yun , Leung, Ann N. , Lynch, David A. , Müller, Néstor L. , Raoof, Suhail, Remy-Jardin, Martine , Ryu, Jay H. , Sholl, Lynette M. , Sverzellati, Nicola , Walsh, Simon , Wells, Athol U. , Bankier, Alexander , Colby, Thomas , Haramati, Linda B , Hariri, Lida P , Inoue, Yoshikazu , Lee, Ho Yun , Leung, Ann , Muller, Nestor , Nicholson, Andrew , Revel, Marie-Pierre , Remy-Jardin, Martine , Richeldi, Luca , Ryu, Jay H , Schiebler, Mark , Sholl, Lynette , White, Charles S , Johannson, Kerri A , Desai, Sujal R. , Haramati, Linda B. , Nicholson, Andrew G. , Richeldi, Luca , Travis, William D.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | August 4, 2025 | Volume: 211 | Issue: 10 | Pages: 1756-1774

10.1164/rccm.202505-1142so | PMID 40758555 Get It

Abstract Background Despite advances in diagnosis and management, the interstitial lung disease (ILD) lexicon is plagued by ambiguous and inconsistent terminology that complicates communication and impedes knowledge generation. The objective of this Fleischner Society Consensus Statement was to produce standardized terminology for ILD multidisciplinary diagnoses and major phenotypes. Methods Interviews with 10 experts were used to identify ILD clinical diagnoses and major phenotypes. The preferred terms for each entity and potential alternatives were identified, alongside the rationale for the preferred term. Entities with more than one potential term were the subject of an online modified Delphi survey posed to the 29 committee members, aiming to achieve consensus. Committee members rated their agreement with the initially preferred term—5 (strongly agree), 4 (agree), 3 (neutral/unsure), 2 (disagree), and 1 (strongly disagree)—with the option to provide additional comments. Median score ≥4 and interquartile range ≤1 were considered consensus agreement. Terms not reaching agreement were discussed by video conference, followed by an additional survey that incorporated feedback. Results From the 60 initial terms, there were two root terms that required upfront consensus before survey initiation (ILD and interstitial pneumonia) and another eight terms that had no alternative suggested by the committee or in the literature. Agreement was met by 47/50 terms (94%) in Round 1 of the survey. The three terms (6%) that did not reach agreement met agreement in Round 2. Conclusions This document provides standardized recommended terms for ILD multidisciplinary diagnoses and major phenotypes that will facilitate communication among clinicians, researchers, patients, and other stakeholders.
Impact of Extending Beta-Lactam Infusions on IV Access Requirements
Kooda, Kirstin , Nelson, Julia, Ausman, Sara , Warfield, Micaela , Zhao, Yanjun , Frazee, Erin N. , Group, on behalf of the Beta Lactam Optimization and Outcomes Management (BLOOM) Study, Kooda, Kirstin J, Abu Saleh, Omar M, Warfield, Micaela N, Nelson, Julia, Ausman, Sara E , Rivera, Christina G. , Saleh, Omar M. Abu, Rule, Andrew D. , Stevens, Ryan W. , Group, on behalf of the Beta Lactam Optimization and Outcomes Management (BLOOM) Study

Mayo Clinic

Critical Care Explorations | August 4, 2025 | Volume: 7 | Issue: 8 | Pages: e1299

10.1097/cce.0000000000001299 | PMID 40758359 Get It

This study aimed to determine if extended infusion (EI; over > 3 hr) beta-lactam therapy increased IV access requirements compared with traditional dosing (TD; over 30 min). Eighty-six adult ICU patients treated with TD anti-pseudomonal beta-lactams who underwent therapeutic drug monitoring (TDM) were included. Patients who transitioned from TD to EI after TDM (EI group) were matched 1:1 to patients who remained on TD. In the primary analysis, the median (interquartile range) total number of lumens in the 24 hours before TDM compared with the 48 hours after TDM were similar between groups (pre: TD 3 [2–5] vs. EI 4 [3–5]; p = 0.22 and post: TD 3 [2–4] vs. EI 4 [3–5]; p = 0.05). Delivery of beta-lactams via EI was not associated with a need for more IV access. Practical challenges such as access should not limit use of EI beta-lactams when indicated.